Sign In
Buy VCYT
$53.19
-0.440 (-0.82%)
At Close: Jun 22, 2026
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
10:52am, Thursday, 11'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Veracyte (VCYT) is a Strong Growth Stock
10:46am, Tuesday, 09'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
01:13pm, Thursday, 04'th Jun 2026
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
12:35pm, Thursday, 04'th Jun 2026
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
05:14pm, Monday, 01'st Jun 2026
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
08:00am, Monday, 01'st Jun 2026
On the heels of the landmark [url="]OPTIMA trial[/url] readout presented at the ASCO Annual Meeting, Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostic
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
07:30am, Monday, 01'st Jun 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BreastCancer--Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
[url="]Veracyte, Inc.[/url] (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the [url="]ENZAMET trial[/url] presented at the
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Delivers Practice-Changing Evidence that Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoi
Veracyte: The Evidence Flywheel Is Turning Into A Cash Flow Platform
05:17am, Thursday, 28'th May 2026
Veracyte is evolving into a multi-cancer clinical decision-making platform, leveraging evidence, payer coverage, and workflow integration for durable growth. Q1 2026 results showed 21% revenue growth,
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?
12:11pm, Wednesday, 27'th May 2026
VCYT gains from strong Afirma and Decipher test growth, but macro pressures and competition pose risks. See what may shape its next move.
Veracyte genomic test identifies breast cancer patients who can skip chemo
07:22am, Wednesday, 27'th May 2026
Today we feature studies to be presented at the year's most important cancer conference, the upcoming American Society of Clinical Oncology meeting in Chicago, all with the potential to be practice
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?
12:20pm, Monday, 25'th May 2026
VCYT jumps 65.8% in a year as Afirma and Decipher volumes surge, guidance lifts, and TrueMRD nears launch with $439M cash and no debt.
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
10:51am, Monday, 25'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
